Please login to the form below

Not currently logged in
Email:
Password:

inflammatory disease

This page shows the latest inflammatory disease news and features for those working in and with pharma, biotech and healthcare.

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Novartis bolsters anti-inflammatory R&D with $1.6bn IFM Tre buy

Following after is a preclinical candidate that is directed at the gastrointestinal tract with potential in inflammatory bowel disease and another that can penetrate the central nervous system that could have ... a role in neurological conditions with

Latest news

More from news
Approximately 1 fully matching, plus 146 partially matching documents found.

Latest Intelligence

  • Galderma launches Rosacea awareness campaign Galderma launches Rosacea awareness campaign

    common inflammatory skin disease. ... Rosacea normally presents varied clinical characteristics, of which the most common are flushing, permanent erythema and inflammatory lesions.

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    The first test of this will be Shire’s new blockbuster-in-waiting Takhzyro, which gained EMA approval in November, for the rare disease hereditary angioedema (HAE). ... Boehringer Ingelheim) for psoriatic arthritis, Crohn’s disease and other

  • 30 Women Leaders in UK Healthcare (part 2) 30 Women Leaders in UK Healthcare (part 2)

    ecosystem. In her 25-plus years in the sector, her investments have resulted in the launch of six drugs, spanning inflammatory and autoimmune disease and cancer.

  • The tipping point The tipping point

    In chronic diseases such as rheumatoid arthritis and inflammatory bowel disease, there are significantly greater savings from switching patients compared with initiating biosimilars in naïve patients alone.

  • Taking a lean and careful approach Taking a lean and careful approach

    Its fully human engineered CD3 antibody Foralumab has reached phase II with potential for a wide range of autoimmune and inflammatory diseases such as non-alcoholic steatohepatitis (NASH), primary biliary cholangitis, ... ulcerative colitis, type 1

More from intelligence
Approximately 0 fully matching, plus 19 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 12 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics